MedPharm are pleased to announce that we have been shortlisted for an award at this year’s CPhI Pharma Awards. We are excited to be selected as finalists for ‘Excellence in Pharma: Analysis, Testing, and Quality Control’ following over 250 submissions.
This year MedPharm have been recognised for our innovative ex vivo models that de-risk client’s topical and transdermal development programmes. We specialise in developing and utilising these models based on human tissue to test the permeation and penetration of drugs and formulations for topical or transdermal routes of delivery. Additionally, these models aim to extend marketing claims and increase the confidence of investors and regulators in client’s submissions.
The awards will take place on 9th October during the annual CPhI Worldwide conference that MedPharm will also be attending. We hope to see you there to celebrate not just our success, but the excellence across our industry. Please follow this link to learn how you can attend this gala.
Notes to editors
MedPharm Ltd. is a leading, global provider of contract topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through proprietary, industry-leading performance testing models. Well-established as a global leader in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm also offers innovative solutions for ophthalmic and airway preparations. These solutions are recognised for their scientific rigour by regulators and investors. MedPharm has fully established R&D centres in the US and U.K. and GMP clinical manufacturing at its global headquarters facility in Guildford, UK.